Trial Profile
A Multi-center, Randomized, Assessor-blinded, Phase II, Parallel Dose-finding Trial in Subjects of ASA Class 1 - 3 to Assess the Efficacy and Safety of 5 Doses of Org 25969 When Administered at 1-2 PTCs After Administration of Zemuron®
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 16 May 2022
Price :
$35
*
At a glance
- Drugs Rocuronium bromide (Primary) ; Sugammadex (Primary)
- Indications Neuromuscular blockade
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme Corp.
- 10 May 2018 New trial record